Skip To Main Content
Osterling Koskinen on Muck Rack

Osterling Koskinen

As seen in: Oxford University Press (OUP), University of Oxford
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Osterling

Contact Osterling, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Efficacy and safety of izokibep in patients with active psoriatic arthritis: a randomised, double-blind, placebo-controlled, phase 2 study

|
By de Vlam, Osterling Koskinen, Abdel-Kader Martin
| University of Oxford
Publication status: In press Peer review status: Peer reviewed Cite APA Style Taylor, P. C., Mease, P. J., de Vlam, K., Mpofu, S., Wetzel, D., Stevens, A. M., Wiens, B., Osterling Koskinen, L., Ohlman, S., Feldwisch, J., Frejd, F. Y., Brun, N. C., Brandt-Juergens, J., Drescher, E., Dokoupilova, E., Rowińska-Osuch, A., Abdel-Kader Martin, N., & Behrens, F. (2025). Efficacy and safety of izokibep in patients with active psoriatic arthritis: a randomised, double-blind, placebo-controlled, phase 2 study.
Open in Who Shared Issue with article?

Izokibep for the treatment of moderate-to-severe plaque psoriasis: a phase II, randomized, placebo-controlled, double-blind, dose-finding multicentre study including long-term treatment

|
By Rosenpark Research, da Mota, Affibody AB, Osterling Koskinen
| Oxford University Press (OUP)
Interleukin (IL)-17 plays a central role in the immunopathogenesis of psoriasis.1,2 This cytokine family, which includes several structurally related proteins designated IL-17A to IL-17F, stimulates T-cell-mediated inflammation and keratinocyte proliferation and helps drive the psoriasis inflammatory cascade.1–3 Blocking IL-17 activity results in a rapid reduction in psoriatic disease severity.3 Most anti-IL-17 agents in clinical use are monoclonal antibodies.
Open in Who Shared Issue with article?
See all 2 articles